{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:13:31Z","timestamp":1793412811324,"version":"4.5.0"},"reference-count":45,"publisher":"Japanese Society of Internal Medicine","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,6,15]]},"DOI":"10.2169\/internalmedicine.2489-18","type":"journal-article","created":{"date-parts":[[2019,2,24]],"date-time":"2019-02-24T22:34:17Z","timestamp":1551047657000},"page":"1665-1672","source":"Crossref","is-referenced-by-count":65,"title":["Dopamine Transporter Imaging in Parkinson Disease: Progressive Changes and Therapeutic Modification after Anti-parkinsonian Medications"],"prefix":"10.2169","volume":"58","author":[{"given":"Ken","family":"Ikeda","sequence":"first","affiliation":[{"name":"Department of Neurology, Toho University Omori Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Ebina","sequence":"additional","affiliation":[{"name":"Department of Neurology, Toho University Omori Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyokazu","family":"Kawabe","sequence":"additional","affiliation":[{"name":"Department of Neurology, Toho University Omori Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Iwasaki","sequence":"additional","affiliation":[{"name":"Department of Neurology, Toho University Omori Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Kaufman MJ, Madras BK. Severe depletion of cocaine recognition sites associated with the dopamine transporter is decreased in the caudate nucleus in Parkinson&apos;s disease. Synapse 9: 43-49, 1991.","DOI":"10.1002\/syn.890090107"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Niznik HB, Fogel EF, Fassos EF, Seeman P. The dopamine transporter is absent in Parkinsonian putamen and reduced in the caudate nucleus. J Neurochem 56: 192-198, 1991.","DOI":"10.1111\/j.1471-4159.1991.tb02580.x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Wilson JM, Levey AI, Rajput A, et al. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson&apos;s disease. Neurology 47: 718-726, 1996.","DOI":"10.1212\/WNL.47.3.718"},{"key":"4","unstructured":"4. Tatsch K, Poepperl G. Nigrostriatal dopamine terminal imaging with dopamine transporter SPECT: an update. J Nucl Med 54: 1331-1338, 2013."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Bajaj N, Hauser RA, Grachev ID. Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes. J Neurol Neurosurg Psychiatry 84: 1288-1295, 2013.","DOI":"10.1136\/jnnp-2012-304436"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Kraemmer J, Kovacs GG, Perju-Dumbrava L, Pirker S, Traub-Weidinger T, Pirker W. Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts. Mov Disord 29: 1767-1773, 2014.","DOI":"10.1002\/mds.25975"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Saari L, Kivinen K, Gardberg M, Joutsa J, Noponen T, Kaasinen V. Dopamine transporter imaging does not predict the number of nigral neurons in Parkinson disease. Neurology 88: 1461-1467, 2017.","DOI":"10.1212\/WNL.0000000000003810"},{"key":"8","unstructured":"8. Kaasinen V, Vahlberg T. Striatal dopamine in Parkinson Disease: a meta-analysis of imaging studies. Ann Neurol 82: 873-882, 2017."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Staffen W, Mair A, Unterrainer J, Trinka E, Ladurner G. Measuring the progression of idiopathic Parkinson&apos;s disease with [<sup>123<\/sup>I] beta-CIT SPECT. J Neural Transm (Vienna) 107: 543-552, 2000.","DOI":"10.1007\/s007020070077"},{"key":"10","unstructured":"10. Nurmi E, Ruottinen HM, Kaasinen V, et al. Progression in Parkinson&apos;s disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT. Ann Neurol 47: 804-808, 2000."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Winogrodzka A, Bergmans P, Booij J, van Royen EA, Janssen AG, Wolters EC. [123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson&apos;s disease. J Neural Transm (Vienna) 108: 1011-1019, 2001.","DOI":"10.1007\/s007020170019"},{"key":"12","unstructured":"12. Chouker M, Tatsch K, Linke R, Pogarell O, Hahn K, Schwarz J. Striatal dopamine transporter binding in early to moderately advanced Parkinson&apos;s disease: monitoring of disease progression over 2 years. Nucl Med Commun 22: 721-725, 2001."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Marek K, Innis R, van Dyck C, et al. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson&apos;s disease progression. Neurology 57: 2089-2094, 2001.","DOI":"10.1212\/WNL.57.11.2089"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson disease progression. JAMA 287: 1653-1661, 2002.","DOI":"10.1001\/jama.287.13.1653"},{"key":"15","unstructured":"15. Pirker W, Djamshidian S, Asenbaum S, et al. Progression of dopaminergic degeneration in Parkinson&apos;s disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study. Mov Disord 17: 45-53, 2002."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Pirker W, Holler I, Gerschlager W, Asenbaum S, Zettinig G, Br\u00fccke T. Measuring the rate of progression of Parkinson&apos;s disease over a 5-year period with beta-CIT SPECT. Mov Disord 18: 1266-1272, 2003.","DOI":"10.1002\/mds.10531"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Winogrodzka A, Bergmans P, Booij J, van Royen EA, Stoof JC, Wolters EC. [(123) I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson&apos;s disease. J Neurol Neurosurg Psychiatry 74: 294-298, 2003.","DOI":"10.1136\/jnnp.74.3.294"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Nurmi E, Bergman J, Eskola O, et al. Progression of dopaminergic hypofunction in striatal subregions in Parkinson&apos;s disease using [18F]CFT PET. Synapse 48: 109-115, 2003.","DOI":"10.1002\/syn.10192"},{"key":"19","unstructured":"19. Schwarz J, Storch A, Koch W, Pogarell O, Radau PE, Tatsch K. Loss of dopamine transporter binding in Parkinson&apos;s disease follows a single exponential rather than linear decline. J Nucl Med 45: 1694-1697, 2004."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Fahn S, Oakes D, Shoulson I, et al.; Parkinson Study Group. Levodopa and the progression of Parkinson&apos;s disease. N Engl J Med 351: 2498-2508, 2004.","DOI":"10.1056\/NEJMoa033447"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Colloby SJ, Williams ED, Burn DJ, Lloyd JJ, McKeith IG, O&apos;Brien JT. Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson&apos;s disease with and without dementia assessed using 123I-FP-CIT SPECT. Eur J Nucl Med Mol Imaging 32: 1176-1185, 2005.","DOI":"10.1007\/s00259-005-1830-z"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Huang C, Tang C, Feigin A, et al. Changes in network activity with the progression of Parkinson&apos;s disease. Brain 130: 1834-1846, 2007.","DOI":"10.1093\/brain\/awm086"},{"key":"23","unstructured":"23. Nandhagopal R, Kuramoto L, Schulzer M, et al. Longitudinal progression of sporadic Parkinson&apos;s disease: a multi-tracer positron emission tomography study. Brain 132: 2970-2979, 2009."},{"key":"24","unstructured":"24. Jakobson Mo S, Linder J, Forsgren L, Holmberg H, Larsson A, Riklund K. Pre- and postsynaptic dopamine SPECT in idiopathic Parkinsonian diseases: a follow-up study. Biomed Res Int 2013: 143532, 2013."},{"key":"25","doi-asserted-by":"publisher","unstructured":"25. Marek K, Seibyl J, Eberly S, et al.; Parkinson Study Group PRECEPT Investigators. Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. Neurology 82: 1791-1797, 2014.","DOI":"10.1212\/WNL.0000000000000424"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Seibyl J, Jennings D, Marek K. Assessment of Parkinson disease progression using 123-I-Ioflupane SPECT: update from Parkinson Progression Marker Initiative Trial (S40.003). Neurology 84 (14 Suppl): 2015.","DOI":"10.1212\/WNL.84.14_supplement.S40.003"},{"key":"27","unstructured":"27. Simuni T, Siderowf A, Lasch S, et al.; Parkinson&apos;s Progression Marker Initiative. Longitudinal change of clinical and biological measures in early Parkinson&apos;s disease: Parkinson&apos;s Progression Markers Initiative Cohort. Mov Disord 33: 771-782, 2018."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Innis RB, Marek KL, Sheff K, et al. Effect of treatment with L-dopa\/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT. Mov Disord 14: 436-442, 1999.","DOI":"10.1002\/1531-8257(199905)14:3<436::AID-MDS1008>3.0.CO;2-J"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Ahlskog JE, Uitti RJ, O&apos;Connor MK, et al. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson&apos;s disease. Mov Disord 14: 940-946, 1999.","DOI":"10.1002\/1531-8257(199911)14:6<940::AID-MDS1005>3.0.CO;2-Y"},{"key":"30","unstructured":"30. Nurmi E, Bergman J, Eskola O, et al. Reproducibility and effect of levodopa on dopamine transporter function measurements: a [18F]CFT PET study. J Cereb Blood Flow Metab 20: 1604-1609, 2000."},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Guttman M, Stewart D, Hussey D, Wilson A, Houle S, Kish S. Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology 56: 1559-1564, 2001.","DOI":"10.1212\/WNL.56.11.1559"},{"key":"32","unstructured":"32. Rossi C, Genovesi D, Marzullo P, et al. Striatal dopamine transporter modulation after rotigotine: results from a pilot single-photon emission computed tomography study in a group of early stage Parkinson disease patients. Clin Neuropharmacol 40: 34-36, 2017."},{"key":"33","unstructured":"33. Ikeda K, Yanagihashi M, Miura K, et al. Zonisamide cotreatment delays striatal dopamine transporter reduction in Parkinson disease: a retrospective, observational cohort study. J Neurol Sci1 391: 5-9, 2018."},{"key":"34","unstructured":"34. Guttman M, Burkholder J, Kish SJ, et al. [11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson&apos;s disease: implications for the symptomatic threshold. Neurology 48: 1578-1583, 1997."},{"key":"35","unstructured":"35. Uno H, Kurokawa M, Masuda Y, Nishimura H. Studies on 3-substituted 1.2-benzisoxazole derivatives 6: syntheses of 3-(sulfamoylmethyl)-1,2- benzisoxazole derivatives and their anticonvulsant activities. J Med Chem 22: 180-183, 1979."},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Murata M, Horiuchi E, Kanazawa I. Zonisamide has beneficial effects on Parkinson&apos;s disease patients. Neurosci Res 41: 397-399, 2001.","DOI":"10.1016\/S0168-0102(01)00298-X"},{"key":"37","doi-asserted-by":"publisher","unstructured":"37. Murata M, Hasegawa K, Kanazawa I. The Japan Zonisamide on PD Study Group. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology 68: 45-50, 2007.","DOI":"10.1212\/01.wnl.0000250236.75053.16"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Ikeda K, Hanashiro S, Sawada M, Iwasaki Y. Preliminary study of zonisamide monotherapy in <i>de novo<\/i> patients with early Parkinson&apos;s disease. Neurol Clin Neurosci 3: 163-166, 2015.","DOI":"10.1111\/ncn3.179"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Asanuma M, Miyazaki I, Diaz-Corrales FJ, Miyoshi K, Ogawa N, Murata NM. Preventing effects of a novel anti-parkinsonian agent zonisamide on dopamine quinone formation. Neurosci. Res 60: 106-113, 2008.","DOI":"10.1016\/j.neures.2007.10.002"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Murata M. Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson&apos;s disease. Curr. Pharm. Des 10: 687-693, 2004.","DOI":"10.2174\/1381612043453180"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Rock DM, Macdonald RL, Taylor CP. Blockade of sustained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD 810, CI 912), a novel anticonvulsant. Epilepsy Res 3: 138-143, 1989.","DOI":"10.1016\/0920-1211(89)90041-7"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Schauf CL. Zonisamide enhances slow sodium inactivation in Myxicola. Brain Res 413: 185-188, 1987.","DOI":"10.1016\/0006-8993(87)90168-5"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Suzuki S, Kawakami K, Nishimura S, et al. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res 12: 21-27, 1992.","DOI":"10.1016\/0920-1211(92)90087-A"},{"key":"44","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1059-1311(96)80104-X","volume":"5","author":"M Kito","year":"1996","unstructured":"44. Kito M, Maehara M, Watanabe K. Mechanisms of T-type calcium channel blockade by zonisamide. Seizure 5: 115-119, 1996.","journal-title":"Seizure","ISSN":"https:\/\/id.crossref.org\/issn\/1059-1311","issn-type":"print"},{"key":"45","doi-asserted-by":"publisher","unstructured":"45. Hong JY, Oh JS, Lee I, et al. Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in <i>de novo<\/i> Parkinson disease. Neurology 82: 1597-1604, 2014.","DOI":"10.1212\/WNL.0000000000000385"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/12\/58_2489-18\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T02:33:20Z","timestamp":1721010800000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/12\/58_2489-18\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,15]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.2489-18","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,15]]}}}